Home8QQ • FRA
AbCellera Biologics Inc
€2.34
Set 30, 6:16:23 PM GMT+2 · EUR · FRA · Disclaimer
StockSegurong nakalista sa DEMay headquarter sa CA
Nakaraang pagsara
€2.30
Sakop ng araw
€2.31 - €2.34
Sakop ng taon
€2.17 - €5.43
Market cap
815.30M USD
Average na Volume
159.00
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Mga balita tungkol sa merkado
Mga Financial
Income Statement
Kita
Net na kita
(USD)Hun 2024Y/Y na pagbabago
Kita
7.32M-27.18%
Gastos sa pagpapatakbo
59.85M139.67%
Net na kita
-36.93M-20.97%
Net profit margin
-504.30-66.12%
Kita sa bawat share
-0.13-18.18%
EBITDA
-56.93M-24.36%
Aktuwal na % ng binabayarang buwis
23.36%
Kabuuang asset
Kabuuang sagutin
(USD)Hun 2024Y/Y na pagbabago
Cash at mga panandaliang investment
670.36M-15.75%
Kabuuang asset
1.41B-8.11%
Kabuuang sagutin
301.51M-11.93%
Kabuuang equity
1.11B
Natitirang share
294.67M
Presyo para makapag-book
0.61
Return on assets
-16.25%
Return on capital
-19.58%
Net change in cash
(USD)Hun 2024Y/Y na pagbabago
Net na kita
-36.93M-20.97%
Cash mula sa mga operasyon
-29.97M-250.56%
Cash mula sa pag-invest
52.10M251.49%
Cash mula sa financing
2.65M532.70%
Net change in cash
24.74M286.42%
Malayang cash flow
-42.55M-1,686.49%
Tungkol
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology firm that researches and develops human antibodies. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia. Wikipedia
Itinatag
2012
Mga Empleyado
586
Search
I-clear ang paghahanap
Isara ang paghahanap
Mga app ng Google
Pangunahing menu